ALSO NOTED: Acorda shares bounce on new data; Endo CEO hits the exit door; BioSante in protocol deal; and much more...

> Shares of Acorda Therapeutics took a big bounce yesterday when the company announced new data demonstrating that its multiple sclerosis drug Fampridine-SR does not raise heart-related risks higher than a placebo. Release

> Endo Pharmaceuticals CEO Peter Lankau has handed in his walking papers. Endo says he is leaving March 1 and will be replaced by its COO and CFO on an interim basis. Release

> BioSante Pharmaceuticals has reached agreement with the FDA on a special protocol assessment for its Phase III trials for LibiGel--a therapy for female sexual dysfunction. Report

> Following a recommendation from the FDA, NPS Pharmaceuticals is preparing a confirmatory late-stage study of Gattex in patients with short bowel syndrome. Report

> Shares of Medarex were buoyed yesterday by an analyst's remark that its cancer drug--ipilimumab--which delivered disappointing data in December, may yet demonstrate its ability to improve overall survival rates. Report

> Amsterdam-based Pharming says it expects a final EMEA decision on Rhucin in the second quarter and is close to detailing its request that the EMEA reexamine its application to market Rhucin in Europe. Report

> The FDA issued a warning letter to Replidyne regarding antibiotic faropenem medoxomil 300 mg. Letter

> Pipex Pharmaceuticals announced that its New Drug Application for oral tetrathiomolybdate has not been accepted by the FDA for further review as submitted. Release

> As if questions about the effectiveness of cholesterol meds weren't enough, now research is casting blood pressure remedies into doubt. Report

> Workers at Pfizer's Terre Haute, Indiana, plant where the ill-fated Exubera was made are, shall we say, less than exuberant today. The company has decided to cut 660 jobs there. Report

And Finally... Here's a troubling milestone: Bird flu deaths in Indonesia have hit 100. Report

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.